Noopept: injectable stroke formulation — RU2330680C2
Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Рита Ушеровна Островска (RU), Рита Ушеровна Островская, тин Борис Михайлович П (RU), Борис Михайлович Пятин, Тать на Александровна Воронина (RU), Татьяна Александровна Воронина, Тать на Александровна Гудашева (RU), Татьяна Александровна Гудашева, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевска (RU), Любовь Николаевна Грушевская · 2008 · RU2330680C2 · patent family 38314867
Published 2008-08-10.
Reported patent results
Reported findings
Several histological and behavioral measures favored Noopept, while not every cortical section differed.
Injectable Noopept experiments in a rat cerebral-ischemia model, including a histology subset of 9 treated and 8 saline animals.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortical injury score: section 1 | 0.06 ± 0.01 treated versus 0.50 ± 0.11 saline | Histology subset; ordinal injury score · p<0.05 |
| Cortical injury score: section 3 | 0.80 ± 0.20 versus 1.38 ± 0.22 | Sections 4–5 were not marked significant · p<0.05 for section 3 |
| Passive-avoidance retention | 67% or 60% in two treated conditions versus 30% ischemia/saline and 92% non-ischemic control | Different treatment schedules; not human memory restoration · Day 7 |
Animal injury models, surviving-animal behavioral analysis and multiple endpoints limit inference. An injectable formulation patent is not proof of human stroke benefit or approval.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The claims concern an injectable Noopept formulation proposed for acute ischemic stroke.
A formulation patent does not establish regulatory approval, clinical stroke benefit or interchangeability with oral preparations.
- Publication
- RU2330680C2 ↗ · 2008-08-10
- Earliest priority / filing
- 2005-12-09 / 2005-12-09
- Original applicant / assignee
- Государственное учреждение Научно-исследовательский институт фармакологии имени В.В. Закусова Российской академии медицинских наук
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 38314867 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Injection dosage form for acute stroke treatment, method of production and application thereof
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Рита Ушеровна Островска (RU); Рита Ушеровна Островская; тин Борис Михайлович П (RU); Борис Михайлович Пятин; Тать на Александровна Воронина (RU); Татьяна Александровна Воронина; Тать на Александровна Гудашева (RU); Татьяна Александровна Гудашева; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевска (RU); Любовь Николаевна Грушевская.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A formulation patent does not establish regulatory approval, clinical stroke benefit or interchangeability with oral preparations.
- Animal injury models, surviving-animal behavioral analysis and multiple endpoints limit inference. An injectable formulation patent is not proof of human stroke benefit or approval.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-38314867. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Рита Ушеровна Островска (RU), Рита Ушеровна Островская, тин Борис Михайлович П (RU), Борис Михайлович Пятин, Тать на Александровна Воронина (RU), Татьяна Александровна Воронина, Тать на Александровна Гудашева (RU), Татьяна Александровна Гудашева, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевска (RU), Любовь Николаевна Грушевская. Noopept: injectable stroke formulation — RU2330680C2 RU2330680C2 · patent family 38314867 2008.
Molekul research summary: https://molekul.io/research/patent-ru2330680c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry